1. Medtronic, 2. Aurinia Pharmaceuticals Inc., 3. Canadawide Scientific, 4. New Beta Innovation Canada Limited, 5. Cyclica, 6. Centre for Commercialization of Regenerative Medicine (CCRM), 7. Deep Genomics, 8. Inversago Pharma, 9. Virogin Biotech, 10. BlueRock Therapeutics. Canada is a particularly developed country in the field of biotechnology. This country has made great contributions to the development of the world in this field. Join the toplist to find out the largest biotech companies in Canada!
- Aurinia Pharmaceuticals Inc.
- Canadawide Scientific
- New Beta Innovation Canada Limited
- Centre for Commercialization of Regenerative Medicine (CCRM)
- Deep Genomics
- Inversago Pharma
- Virogin Biotech
- BlueRock Therapeutics
Medtronic is a global healthcare solutions company that was founded in 1949 and has been operating in Canada for over 50 years. This is one of the largest biotech companies in Canada. The company specializes in medical devices and technologies for the treatment of chronic diseases such as diabetes, heart disease, and spinal conditions.
Medtronic’s Canadian headquarters is located in Brampton, Ontario, where the company has a dedicated team of over 1,800 employees working in research and development, manufacturing, sales, and marketing. Medtronic has a strong presence in the Canadian healthcare system, with partnerships with hospitals, clinics, and healthcare professionals across the country.
Medtronic’s product portfolio includes insulin pumps, pacemakers, defibrillators, spinal implants, and other medical devices that are designed to improve the quality of life for patients with chronic diseases. The company is committed to innovation and invests heavily in research and development to bring new and improved products to market.
In addition to its focus on medical devices, Medtronic is also committed to improving patient outcomes through patient education and support programs. The company’s programs are designed to help patients manage their conditions, improve their quality of life, and reduce healthcare costs.
Headquarters: Brampton, Ontario
Photo by sanjeri on Unsplash
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of autoimmune diseases. The company’s lead product is called voclosporin, which is a calcineurin inhibitor that is currently being developed for the treatment of lupus nephritis, a serious autoimmune disease that affects the kidneys.
Aurinia Pharmaceuticals was founded in 1993 and is headquartered in Victoria, British Columbia, Canada. The company’s mission is to improve the lives of people with autoimmune diseases by developing innovative and effective therapies. Aurinia Pharmaceuticals has a team of experienced scientists, researchers, and business professionals who are dedicated to advancing the company’s pipeline of drug candidates.
In addition to voclosporin, Aurinia Pharmaceuticals has several other drug candidates in its pipeline, including a therapeutic antibody for the treatment of IgA nephropathy, a chronic kidney disease. The company is also exploring the potential of its technology platform to develop therapies for other autoimmune diseases, such as multiple sclerosis and psoriasis.
Overall, Aurinia Pharmaceuticals is a promising company that is focused on developing innovative therapies for the treatment of autoimmune diseases. With a strong pipeline of drug candidates and a dedicated team of professionals, the company is well-positioned to make a significant impact in the field of biopharmaceuticals.
Headquarters: Victoria, Canada
Photo by Chagin on Unsplash
Canadawide Scientific which is one of the largest biotech companies in Canada is a leading supplier of scientific and laboratory equipment in Canada. The company was established in 2002 with the aim of providing high-quality laboratory equipment and supplies to research institutions, universities, and government agencies across the country.
Canadawide Scientific offers a wide range of products such as chemicals, equipment, instruments, glassware, plastic ware, and other laboratory essentials. The company has partnerships with leading manufacturers from around the world, ensuring that their products are of the highest quality and meet the needs of their clients.
Headquarters: Ottawa, Canada
Photo by Sean Anthony Eddy on Unsplash
Photo by gorodenkoff on Unsplash
New Beta Innovation Canada Limited
New Beta Innovation Canada Limited is a Canadian-based biotechnology company that focuses on developing innovative solutions for the healthcare industry. The company was founded in 2007 and has since been committed to improving people’s lives through cutting-edge research and development.
New Beta Innovation Canada Limited specializes in developing novel therapies for a variety of diseases, including cancer, diabetes, and autoimmune disorders. The company’s approach is based on using advanced technologies and scientific expertise to create safe and effective treatments that can significantly improve patients’ health outcomes.
In addition to its research and development efforts, New Beta Innovation Canada Limited also offers a range of services to support the biotech industry, including consulting, manufacturing, and clinical trial management. The company is dedicated to providing its clients with the support they need to bring their products to market and improve patient care.
New Beta Innovation Canada Limited is a leading biotechnology company that is committed to advancing healthcare through innovative solutions. Its focus on research and development, as well as its dedication to supporting the biotech industry, makes it a valuable partner for anyone looking to improve patient outcomes.
Headquarters: Burnaby, Canada
Photo by TwilightShow on Unsplash
Photo by RephiLe water on Unsplash
The Toronto-based biotechnology startup Cyclica uses biophysics and artificial intelligence (AI) to accelerate, secure, and reduce the cost of medication discovery. By providing an integrated network of technology to all scientists in the pharmaceutical industry, they allow drug discovery and revolutionize a system plagued by attrition and expensive failures. Cyclica is one of the largest biotech companies in Canada
In order to provide light on target discovery, drug action mechanisms, lead prioritization, and drug repurposing, their cloud-based Ligand Express platform de novo reveals the polypharmacological profiles of small compounds. By examining the effects of genetic variations on protein structure, they have increased the utility of Ligand Express downstream and gained an understanding of structural pharmacogenomics.
The complexity of the disease is embraced by Cyclica from molecule to treatment. With strong industry ties, a cutting-edge platform, and a ground-breaking decentralized collaboration approach, Cyclica is more precisely developing medications to meet unmet patient needs. Their work includes numerous joint ventures and numerous collaborations with major pharma and biotech companies. Cyclica is a committed group of biotech and pharmaceutical industry experts, biologists, chemists, and computer scientists who work at the nexus of their respective fields of specialization.
Photo by Arnon Mungyodklang on Unsplash
Centre for Commercialization of Regenerative Medicine (CCRM)
The Centre for Commercialization of Regenerative Medicine (CCRM) provides strategic funding, dedicated infrastructure, and specialised business and scientific knowledge to enable the commercialization of regenerative medicine technologies, as well as cell and gene treatments.
The Canadian federal government, the province of Ontario, and top academic and business partners all contribute to the funding of CCRM, a global public-private collaboration with its headquarters in Canada. With an emphasis on cell and gene therapy, it promotes the development of regenerative drugs and related enabling technologies. A facility for cell and viral vector production that complies with good manufacturing practices is part of CCRM’s 40,000 square foot advanced cell manufacturing facility. Through CCRM, the development of new businesses and patient-marketable products is sped up. The thriving biotech sector in Toronto is greatly influenced by CCRM.
With specialized teams, finance, and infrastructure, CCRM—a network of researchers, top businesses, strategic investors, and entrepreneurs—accelerates the conversion of scientific discoveries into new businesses and sellable goods for patients. The Ontario Institute for Regenerative Medicine and Medicine by Design at the University of Toronto collaborates with CCRM on commercialization.
Photo by National Cancer Institute on Unsplash
Alliance for Regenerative Medicine
Deep Genomics creates its own unique artificial intelligence (AI), which is then used to find fresh approaches to reverse the effects of genetic mutations and create individualized treatments. Brendan Frey, the founder of their company, contributed to the development of the incredibly popular artificial intelligence technique known as “deep learning” in 1995. Everything is changing because of this technology, from farmers producing better crops to cell phones transcribing speech to text.
With more than 100 team members, Deep Genomics has experience in a variety of fields, including molecular genetics, artificial intelligence, automation, cell, and molecular biology, clinical development, in vitro disease models, machine learning, medicine, and software engineering. The top 1% of new graduates and seasoned professionals working at the nexus of genetics, drug development, and AI are who Deep Genetics chooses to hire..
The use of AI and machine learning to mine the human genome for knowledge about how diseases occur and to program medicines to treat them is being pioneered by Deep Genomics. Their in-house developed AI Workbench decodes enormous volumes of RNA biology data, identifies fresh targets for treating genetically determined disorders, and generates top-notch treatment programs to do so. AI Workbench 3.0 is a project that Deep Genomics is currently developing to study increasingly complicated genetic illnesses.
Photo by AnnaStills on Unsplash
Inversago Pharma is a Canadian biopharmaceutical company focused on the development of innovative therapies for the treatment of metabolic diseases, including obesity and metabolic syndrome. The company is dedicated to addressing unmet medical needs in these areas through its research and development efforts.
Inversago Pharma specializes in targeting the peripheral cannabinoid receptor type 1 (CB1) pathway. The CB1 receptor is involved in regulating various physiological processes, including appetite, metabolism, and energy balance. By modulating this pathway, Inversago Pharma aims to develop novel therapeutics to help manage and potentially treat metabolic disorders.
Drugs from Inversago that inhibit the cannabinoid receptor type 1 (CB1) protein are being developed to treat metabolic disorders. This protein, which affects functions including hunger and blood sugar regulation, is brought on by the body’s own cannabinoids.
Screenshot of https://inversago.com/en/
Université de Sherbrooke
Notch Therapeutics is a biotechnology company focused on the development of innovative cell therapies for cancer treatment. The company utilizes a proprietary gene-editing technology known as Engineered Thymic Niche (ETN) to engineer and manufacture T cells for targeted cancer therapies.
The ETN platform developed by Notch Therapeutics enables precise control over the programming of T cells, allowing for the generation of customized, tumor-targeting immune cells. By utilizing this platform, the company aims to develop next-generation allogeneic (off-the-shelf) cell therapies with improved efficacy and safety profiles.
One of the key advantages of Notch Therapeutics’ approach is its ability to generate T cells that are designed to specifically recognize and eliminate cancer cells while minimizing damage to healthy tissues. This targeted approach has the potential to enhance the therapeutic response and reduce side effects associated with traditional cancer treatments.
Notch Therapeutics is also working on expanding its technology to develop therapies for other diseases beyond cancer. By harnessing the power of gene editing and cellular engineering, the company aims to address unmet medical needs and provide new treatment options for patients.
Headquarters: Vancouver, Canada, and Shanghai, China
Screenshot of https://virogin.com/
Photo by National Cancer Institute on Unsplash
BlueRock Therapeutics is one of the largest biotech companies in Canada. It is committed to developing cell treatments to treat a variety of incurable illnesses. The BlueRock unique cell+gene platform, which was founded in 2016 and bought by Bayer in 2019, provides cell therapies for the three therapeutic areas of neurology, cardiology, and immunology. Particularly, BlueRock Therapeutics has achieved significant strides in the treatment of autoimmune illnesses, Parkinson’s disease, and heart failure.
BlueRock creates cell therapies to restore injured or deteriorated tissue utilizing their Cell plus Gene platform. Engineering microglia for Parkinson’s Disease and other neurological illnesses are the main goals of BlueRock’s neurology pipeline. Their cardiology pipeline involves cell treatment employing cardiomyocytes for heart failure. The company is developing macrophage cell treatments for autoimmune disorders. Ex vivo engineering is a technique employed by BlueRock to allow cells to create therapeutically useful enzymes, antibodies, and other proteins.
BlueRock has revolutionized and scaled methods for producing real cell types in the fields of neurology, cardiology, and immunology. Its work is based on the study of some of the top minds in the field of induced pluripotent stem cell (iPSC) biology.